文献速递认知障碍与痴呆

β-淀粉样蛋白与阿尔茨海默病认知及MRI脑结构关联的遗传调节

Genetic Moderation of the Association of β-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease.
PubMed 文献 · Neurology · 2023-04-21

在A4研究的2953名认知未受损参与者中评估遗传变异与18F-Florbetapir PET SUVR的交互作用对PACC的影响,并在ADNI(N=527)中验证。发现4个遗传变异显著调节Aβ负荷与认知的关联,其中rs76366637在A4中与Aβ SUVR升高时PACC评分降低相关,在ADNI中与认知下降加速和脑萎缩加速相关。

要点

  • A4研究中4个遗传变异显著调节Aβ负荷与认知的关联。
  • rs78021285、rs71567499、rs10974405的次要等位基因与Aβ SUVR升高时PACC额外降低相关。
  • rs7825645的次要等位基因与Aβ SUVR升高时PACC降低较少相关。

核心结论

  • 特定遗传变异导致的认知功能障碍加重和脑萎缩加速模式可能解释临床前和前驱期AD认知异质性的一部分。
  • 位于ARPP21附近的遗传变异rs76366637在A4中与较低认知评分相关,在ADNI中与认知下降加速和脑萎缩加速相关,可能有助于识别AD进展加速风险最高的个体。

研究设计与样本

  • 在A4研究的2953名认知未受损参与者中评估遗传变异与18F-Florbetapir PET SUVR的交互作用对PACC的预测。
  • 在ADNI(N=527)中评估在A4研究中识别的遗传变异与认知未受损和轻度认知障碍参与者的纵向认知和脑萎缩的关联。

主要发现

  • A4研究中,4个遗传变异显著调节Aβ负荷与认知的关联。
  • rs78021285次要等位基因与Aβ SUVR升高时PACC评分额外降低相关(β=-2.29,SE=0.40,p FDR=0.02,最近基因ARPP21)。
  • rs71567499次要等位基因与Aβ SUVR升高时PACC评分额外降低相关(β=-2.16,SE=0.38,p FDR=0.02,最近基因PPARD)。
  • rs10974405次要等位基因与Aβ SUVR升高时PACC评分额外降低相关(β=-1.68,SE=0.29,p FDR=0.02,最近基因GLIS3)。
  • rs7825645次要等位基因与Aβ SUVR升高时PACC评分降低较少相关(β=0.71,SE=0.13,p FDR=0.04,最近基因FGF20)。

临床怎么用

  • 位于ARPP21附近的遗传变异rs76366637可能有助于识别AD进展加速风险最高的个体。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: There is considerable heterogeneity in the association between increasing β-amyloid (Aβ) pathology and early cognitive dysfunction in preclinical Alzheimer disease (AD). At this stage, some individuals show no signs of cognitive dysfunction, while others show clear signs of decline. The factors explaining this heterogeneity are particularly important for understanding progression in AD but remain largely unknown. In this study, we examined an array of genetic variants that may influence the relationships among Aβ, brain structure, and cognitive performance in 2 large cohorts. METHODS: In 2,953 cognitively unimpaired participants from the Anti-Amyloid Treatment in Asymptomatic Alzheimer disease (A4) study, interactions between genetic variants and 18F-Florbetapir PET standardized uptake value ratio (SUVR) to predict the Preclinical Alzheimer Cognitive Composite (PACC) were assessed. Genetic variants identified in the A4 study were evaluated in the Alzheimer Disease Neuroimaging Initiative (ADNI, N = 527) for their association with longitudinal cognition and brain atrophy in both cognitively unimpaired participants and those with mild cognitive impairment. RESULTS: In the A4 study, 4 genetic variants significantly moderated the association between Aβ load and cognition. Minor alleles of 3 variants were associated with additional decreases in PACC scores with increasing Aβ SUVR (rs78021285, β = -2.29, SE = 0.40, p FDR = 0.02, nearest gene ARPP21; rs71567499, β = -2.16, SE = 0.38, p FDR = 0.02, nearest gene PPARD; and rs10974405, β = -1.68, SE = 0.29, p FDR = 0.02, nearest gene GLIS3). The minor allele of rs7825645 was associated with less decrease in PACC scores with increasing Aβ SUVR (β = 0.71, SE = 0.13, p FDR = 0.04, nearest gene FGF20). The genetic variant rs76366637, in linkage disequilibrium with rs78021285, was available in both the A4 and ADNI. In the A4, rs76366637 was strongly associated with reduced PACC scores with increasing Aβ SUVR (β = -1.01, SE = 0.21, t = -4.90, p < 0.001). In the ADNI, rs76366637 was associated with accelerated cognitive decline (χ2 = 15.3, p = 0.004) and atrophy over time (χ2 = 26.8, p < 0.001), with increasing Aβ SUVR. DISCUSSION: Patterns of increased cognitive dysfunction and accelerated atrophy due to specific genetic variation may explain some of the heterogeneity in cognition in preclinical and prodromal AD. The genetic variant near ARPP21 associated with lower cognitive scores in the A4 and accelerated cognitive decline and brain atrophy in the ADNI may help to identify those at the highest risk of accelerated progression of AD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Insel PS, Kumar A, Hansson O, et al. Genetic Moderation of the Association of β-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease. Neurology. 2023. PMID: 37085326. doi:10.1212/WNL.0000000000207305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。